Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) dropped 3.4% during mid-day trading on Monday . The company traded as low as $0.26 and last traded at $0.28, approximately 10,947 shares were traded during mid-day trading. A decline of 98% from the average daily volume of 556,246 shares. The stock had previously closed at $0.29.
PLX has been the subject of a number of research reports. HC Wainwright set a $3.00 price objective on shares of Protalix Biotherapeutics and gave the company a “buy” rating in a report on Friday. Zacks Investment Research upgraded shares of Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th.
Protalix Biotherapeutics (NYSEAMERICAN:PLX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.02). The firm had revenue of $12.25 million for the quarter, compared to the consensus estimate of $11.75 million. During the same period in the prior year, the company earned ($0.08) EPS.
About Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Read More: Is the QQQ ETF safe?
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.